Sjogren's Syndrome - Pipeline Review, Q2 2011

Date: May 1, 2011
Pages: 52
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SA515D7D71BEN
Leaflet:

Download PDF Leaflet

Sjogren's Syndrome - Pipeline Review, Q2 2011
Sjogren's Syndrome – Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Sjogren's Syndrome - Pipeline Review, Q2 2011', provides an overview of the Sjogren's Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Sjogren's Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome. 'Sjogren's Syndrome - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Sjogren's Syndrome.
  • A review of the Sjogren's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Sjogren's Syndrome pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Sjogren's Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Sjogren's Syndrome pipeline depth and focus of Sjogren's Syndrome therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Sjogren's Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Sjogren's Syndrome
Sjogren's Syndrome Therapeutics under Development by Companies
Sjogren's Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Sjogren's Syndrome Therapeutics - Products under Development by Companies
Sjogren's Syndrome Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Sjogren's Syndrome Therapeutics Development
Alcon, Inc.
MAT Biopharma
Pantarhei Bioscience BV
Parion Sciences, Inc.
Sjogren's Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Estetrol - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
P-552 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Allogeneic Mesenchymal Stem Cells - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Limphostat-B - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Rituximab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Raptiva - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MabThera - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mabthera - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Rituximab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Anakinra - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Phytosphingosine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
MAT 304 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Belimumab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
FID 114657 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Hematopoietic Stem Cell Transplantation + Cyclophosphamide + Anti-thymocyte Globulin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Hydroxychloroquine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Rituximab - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Mizoribine - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Sjogren's Syndrome Therapeutics – Drug Profile Updates
Sjogren's Syndrome - Featured News
Apr 08, 2008: Parion Sciences Announces Phase I Clinical Results For Novel Dry Mouth Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 52

LIST OF TABLES

Number of Products Under Development for Sjogren's Syndrome, Q2 2011
Products under Development for Sjogren's Syndrome – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Alcon, Inc., 2011
MAT Biopharma, 2011
Pantarhei Bioscience BV, 2011
Parion Sciences, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Sjogren's Syndrome Therapeutics – Drug Profile Updates 49

LIST OF FIGURES

Number of Products under Development for Sjogren's Syndrome, Q2 2011
Products under Development for Sjogren's Syndrome – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011 27
Sjogren's Syndrome - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Sjogren's Syndrome – Pipeline Review, H2 2012 US$ 2,000.00 Nov, 2012 · 41 pages
Frozen Shoulder Syndrome - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Fragile X Syndrome - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages

Ask Your Question

Sjogren's Syndrome - Pipeline Review, Q2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: